The Accelerated Access Collaborative (AAC) is a unique partnership hosted by NICE which brings together representatives of healthcare landscape organisations and the health technology industry.
The collaborative was formed in response to the independently-chaired 2016 Accelerated Access Review which set out a vision of getting the best technologies to patients more quickly and cheaply, in a system that's quick to adopt innovation.
The AAC focuses on aligning activities to get highly transformative technologies to NHS patients quickly through the introduction of a specific Accelerated Access Pathway (AAP). The AAP sits alongside the ITT, ITP and NIA schemes as another available route for innovations to be nationally prioritised for rapid uptake.
Wessex AHSN is supporting the spread and adoption of innovations identified by the AAC through our Nationally Prioritised Innovations Programme. We are currently planning our approach following the announcement in October 2018 of the first seven innovations selected for rapid uptake.
We will share further information here as it becomes available. If you have any queries or would like to know more please get in touch.
The innovations included in the AAC are:
- Urolift for lower urinary tract symptoms of benign prostatic hyperplasia – A cost-saving device that relieves painful urinary tract symptoms in men.
- HeartFlow Analysis for estimating fractional flow reserve from coronary CT angiography – A non-invasive personalised cardiac test that reduces the need for unnecessary procedures.
- Placental growth factor (PIG-F) based testing for suspected pre-eclampsia – Tests for early diagnosis of pre-eclampsia in pregnant women, which if unmonitored, can cause serious complications for mother and baby.
- PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia – Cost effective drugs that significantly lower cholesterol and fats in the blood in patients at increased risk of heart disease and narrowed arteries.
- High sensitivity troponin tests for early rule out of myocardial infarction – Diagnostic tests that detect whether or not a patient is at risk or previously had a heart attack.
- Quantitative faecal immunochemical tests for colorectal cancer – Diagnostic tests that reduce referrals for patients with suspected colorectal cancer.
- Cladribine for treating highly active relapsing-remitting multiple sclerosis in adults – A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden.